Evidence map›Paper›PMID 36262353›Full record

ArticleJournal of oncology2022

Long Noncoding RNA LINC00909 Induces Epithelial-Mesenchymal Transition and Contributes to Osteosarcoma Tumorigenesis and Metastasis.

Wanshun Liu, Qi Zhang, Kai Shen, Keran Li, Jie Chang, He Li, Ao Duan, Sheng Zhang, Yumin Huang

Abstract read
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wanshun LiuDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.ORCID https://orcid.org/0000-0002-9722-9922
Qi ZhangDepartment of Pain Management, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211100, China.ORCID https://orcid.org/0000-0002-7420-3965
Kai ShenDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.ORCID https://orcid.org/0000-0003-4699-1869
Keran LiDepartment of Cataract, The Affiliated Eye Hospital of Nanjing Medical University, 138 Hanzhong Road, Nanjing, 210003 Jiangsu, China.
Jie ChangDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.
He LiDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.
Ao DuanDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.
Sheng ZhangDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.ORCID https://orcid.org/0000-0002-5448-9564
Yumin HuangDepartment of Orthopedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road Nanjing, 210029 Jiangsu, China.ORCID https://orcid.org/0000-0002-8756-5746

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteosarcoma (OS) is a malignant tumor that is highly metastatic with a high mortality rate. Although mounting evidence suggests that LINC00909 is strongly associated with the malignant progression of various tumors, the exact role of LINC00909 in OS remains unknown. Therefore, the current study was designed to investigate the relationship between LINC00909 and the malignant progression of OS. Methods: LINC00909 expression was measured in OS cell lines and clinical specimens using RT-qPCR assays. The effects of LINC00909 on OS proliferation, invasion, and migration were calculated both in vitro and in vivo. Apart from that, bioinformatics analyses, FISH, RIP, and luciferase reporter assays were carried out to investigate the downstream target of LINC00909. Rescue experiments were also conducted to investigate the potential mechanisms of action of competitive endogenous RNAs (ceRNAs). Results: In this study, we found that LINC00909 was highly expressed in OS cell lines and clinical specimens. In vivo and in vitro experiments demonstrated that LINC00909 induces epithelial-to-mesenchymal transition (EMT) and contributes to OS tumorigenesis and metastasis. FISH, RIP, and luciferase assays indicated that miR-875-5p is a direct target of LINC00909. Moreover, HOXD9 was validated as the downstream target of miR-875-5p in a luciferase reporter assay and western blotting experiments. Rescue experiments revealed that HOXD9 reversed the effect of LV-sh-LINC00909 on OS cells by positively regulating the PI3K/AKT/mTOR signaling pathway. Conclusion: Collectively, LINC00909 induces EMT and contributes to OS tumorigenesis and metastasis through the PI3K/AKT/mTOR pathway by binding to miR-875-5p to upregulate HOXD9 expression. Targeting the LINC00909/miR-875-5p/HOXD9 axis may have potential in treating OS.

Identifiers

PMID36262353
PMCPMC9576421

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.